The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Steatosis and lobular inflammation scores were independently evaluated by a pathologist in a blinded fashion according to the rodent MASLD scoring system.
“Steatosis and lobular inflammation scores were independently evaluated by a pathologist in a blinded fashion according to the rodent MASLD scoring system.58”
From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Flagged first, then by citations
Research works printed but not linked: 26
- M Lazo, 2008, The epidemiology of nonalcoholic fatty liver disease: A global perspective, Semin Liver Dis, 28, 339, 10.1055/s-0028-1091978 · DOI
- CD Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 · DOI
- DG Tiniakos, 2010, Nonalcoholic fatty liver disease: Pathology and pathogenesis, Annu Rev Pathol, 5, 145, 10.1146/annurev-pathol-121808-102132 · DOI · Paper page
- ZM Younossi, 2008, Review article: Current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 28, 2, 10.1111/j.1365-2036.2008.03710.x · DOI
- DE Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
- EM Brunt, 1999, Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions, Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x · DOI · Paper page
- AM van den Maagdenberg, 1993, Transgenic mice carrying the apolipoprotein E3-leiden gene exhibit hyperlipoproteinemia, J Biol Chem, 268, 10540, 10.1016/S0021-9258(18)82232-3 · DOI
- PM Nishina, 1990, Synthetic low and high fat diets for the study of atherosclerosis in the mouse, J Lipid Res, 31, 859, 10.1016/S0022-2275(20)42785-3 · DOI
- XC Jiang, 1992, Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. dependence on natural flanking sequences, J Clin Invest, 90, 1290, 10.1172/JCI115993 · DOI
- AM van den Hoek, 2014, APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome, Diabetes Obes Metab, 16, 537, 10.1111/dom.12252 · DOI
- M Westerterp, 2006, Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-leiden mice, Arterioscler Thromb Vasc Biol, 26, 2552, 10.1161/01.ATV.0000243925.65265.3c · DOI
- L Verschuren, 2009, MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease, Circ Res, 105, 99, 10.1161/CIRCRESAHA.109.199166 · DOI
- Munro B (1997) Statistical methods for health care research. New York: Lippincott Williams & Willkins.
- EM Brunt, 2010, Pathology of nonalcoholic fatty liver disease, Nat Rev Gastroenterol Hepatol, 7, 195, 10.1038/nrgastro.2010.21 · DOI · Paper page
- EM Brunt, 2001, Nonalcoholic steatohepatitis: Definition and pathology, Semin Liver Dis, 21, 3, 10.1055/s-2001-12925 · DOI
- P Bedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI
- C Lackner, 2011, Hepatocellular ballooning in nonalcoholic steatohepatitis: The pathologist's perspective, Expert Rev Gastroenterol Hepatol, 5, 223, 10.1586/egh.11.8 · DOI
- S Caldwell, 2010, Hepatocellular ballooning in NASH, J Hepatol, 53, 719, 10.1016/j.jhep.2010.04.031 · DOI
- W Liang, 2014, Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1beta-induced chronic inflammation, Lab Invest, 94, 491, 10.1038/labinvest.2014.11 · DOI
- DE Kleiner, 2012, Nonalcoholic fatty liver disease: Pathologic patterns and biopsy evaluation in clinical research, Semin Liver Dis, 32, 3, 10.1055/s-0032-1306421 · DOI
- NS Goldstein, 2005, Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens, Am J Clin Pathol, 123, 382, 10.1309/EY72F1EN9XCB1KXX · DOI
- ZM Younossi, 1998, Nonalcoholic fatty liver disease: Assessment of variability in pathologic interpretations, Mod Pathol, 11, 560
- T Fukusato, 2005, Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis, Hepatol Res, 33, 122, 10.1016/j.hepres.2005.09.018 · DOI
- RB Merriman, 2006, Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease, Hepatology, 44, 874, 10.1002/hep.21346 · DOI
- R Vuppalanchi, 2009, Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 481, 10.1016/j.cgh.2008.12.015 · DOI
- R Juluri, 2011, Generalizability of the nonalcoholic steatohepatitis clinical research network histologic scoring system for nonalcoholic fatty liver disease, J Clin Gastroenterol, 45, 55, 10.1097/MCG.0b013e3181dd1348 · DOI
Cited by
Sorted by citations
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Wang, X., Zheng, Z., Caviglia, J. M., Corey, K. E., Herfel, T. M., Cai, B., Masia, R., Chung, R. T., Lefkowitch, J. H., Schwabe, R. F., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.016 · Cited by 413
Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD
Carpino, G., Del Ben, M., Pastori, D., Carnevale, R., Baratta, F., Overi, D., Francis, H., Cardinale, V., Onori, P., Safarikia, S., et al. (2020) · Hepatology · doi:10.1002/hep.31056 · Cited by 381
Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01043-6 · Cited by 262
Self-citationChiu, C.-C., Ching, Y.-H., Li, Y.-P., Liu, J.-Y., Huang, Y.-T., Huang, Y.-W., Yang, S.-S., Huang, W.-C., & Chuang, H.-L. (2017) · Nutrients · doi:10.3390/nu9111220 · Cited by 160
Boland, M. L., Oró, D., Tølbøl, K. S., Thrane, S. T., Nielsen, J. C., Cohen, T. S., Tabor, D. E., Fernandes, F., Tovchigrechko, A., Veidal, S. S., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4904 · Cited by 129
Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice
Arnoldussen, I. A. C., Wiesmann, M., Pelgrim, C. E., Wielemaker, E. M., van Duyvenvoorde, W., Amaral-Santos, P. L., Verschuren, L., Keijser, B. J. F., Heerschap, A., Kleemann, R., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.52 · Cited by 101
Self-citationTranscriptional regulation of Hepatic Stellate Cell activation in NASH
Marcher, A.-B., Bendixen, S. M., Terkelsen, M. K., Hohmann, S. S., Hansen, M. H., Larsen, B. D., Mandrup, S., Dimke, H., Detlefsen, S., & Ravnskjaer, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-39112-6 · Cited by 95
In Kim, H., Kim, J.-K., Kim, J.-Y., Jang, S.-E., Han, M. J., & Kim, D.-H. (2019) · Nutrition Research · doi:10.1016/j.nutres.2019.03.008 · Cited by 82
Wang, Z., Zhu, S., Jia, Y., Wang, Y., Kubota, N., Fujiwara, N., Gordillo, R., Lewis, C., Zhu, M., Sharma, T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.014 · Cited by 72
Lu, W., Mei, J., Yang, J., Wu, Z., Liu, J., Miao, P., Chen, Y., Wen, Z., Zhao, Z., Kong, H., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117601 · Cited by 65
van Koppen, A., Verschuren, L., van den Hoek, A. M., Verheij, J., Morrison, M. C., Li, K., Nagabukuro, H., Costessi, A., Caspers, M. P. M., van den Broek, T. J., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.10.001 · Cited by 58
Self-citationDave, N., Judd, J. M., Decker, A., Winslow, W., Sarette, P., Villarreal Espinosa, O., Tallino, S., Bartholomew, S. K., Bilal, A., Sandler, J., et al. (2023) · Aging Cell · doi:10.1111/acel.13775 · Cited by 55
Bórquez, J. C., Díaz-Castro, F., La Fuente, F. P.-D., Espinoza, K., Figueroa, A. M., Martínez-Ruíz, I., Hernández, V., López-Soldado, I., Ventura, R., Domingo, J. C., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2023.155765 · Cited by 54
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Zhang, Y., Zhang, M., Jiang, S., Hu, H., Wang, X., Yu, F., Huang, Y., & Liang, Y. (2024) · Cancer Causes & Control · doi:10.1007/s10552-024-01865-5 · Cited by 5
Somatic mutations in TBX3 promote hepatic clonal expansion by accelerating VLDL secretion
Mannino, G., Quinn, G., Zhu, M., Wang, Z., Wang, X., Li, B., Hsieh, M.-H., Mathews, T., Zacharias, L., Gu, W., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191855 · Cited by 4
Metadata
- Authors
- Liang, W., Menke, A. L., Driessen, A., Koek, G. H., Lindeman, J. H., Stoop, R., Havekes, L. M., Kleemann, R., & van den Hoek, A. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-12-23
- Volume
- 9
- Issue
- 12
- Pages
- e115922
- ISSN
- 1932-6203
- PMC
- PMC4275274
- Cited by
- 577
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
